Home/Meiji Seika Pharma/Yoshihiko Kawasaki
YK

Yoshihiko Kawasaki

Senior Managing Executive Officer, Head of R&D

Meiji Seika Pharma

Meiji Seika Pharma Pipeline

DrugIndicationPhase
ME1100 (arbekacin inhalation solution)Pulmonary infections caused by multidrug-resistant pathogensPhase 3
CefiderocolInfections caused by multidrug-resistant Gram-negative bacteriaApproved
Various oncology candidatesMultiple cancer typesVarious